Helius Medical Technologies Appoints New CMO
Ticker: HSDT · Form: 8-K · Filed: Jun 28, 2024 · CIK: 1610853
| Field | Detail |
|---|---|
| Company | Helius Medical Technologies, Inc. (HSDT) |
| Form Type | 8-K |
| Filed Date | Jun 28, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, board-of-directors, corporate-governance
TL;DR
Helius Medical Technologies brings back Dr. Hudson as CMO, signaling a renewed focus on medical leadership.
AI Summary
Helius Medical Technologies, Inc. announced on June 27, 2024, the appointment of Dr. Jonathan S. B. T. Hudson as Chief Medical Officer. Dr. Hudson previously served as Chief Medical Officer of the Company from January 2023 to December 2023 and rejoined the Company in the same capacity. The company also reported on the election of directors and the submission of matters to a vote of security holders.
Why It Matters
The appointment of a Chief Medical Officer is crucial for guiding the company's medical strategy and product development, potentially impacting future clinical trials and regulatory approvals.
Risk Assessment
Risk Level: low — This filing primarily concerns executive appointments and routine corporate governance matters, with no immediate financial or operational risks disclosed.
Key Players & Entities
- Helius Medical Technologies, Inc. (company) — Registrant
- Dr. Jonathan S. B. T. Hudson (person) — Chief Medical Officer
- June 27, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the Chief Medical Officer of Helius Medical Technologies, Inc.?
Dr. Jonathan S. B. T. Hudson has been appointed as the Chief Medical Officer.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on June 27, 2024.
What is the exact name of the registrant?
The exact name of the registrant is HELIUS MEDICAL TECHNOLOGIES, INC.
In which state was Helius Medical Technologies, Inc. incorporated?
Helius Medical Technologies, Inc. was incorporated in Delaware.
What is the SIC code for Helius Medical Technologies, Inc.?
The Standard Industrial Classification (SIC) code for Helius Medical Technologies, Inc. is 3845, which corresponds to ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS.
Filing Stats: 1,035 words · 4 min read · ~3 pages · Grade level 14.4 · Accepted 2024-06-28 16:15:13
Key Financial Figures
- $0.001 — hich registered Class A Common Stock, $0.001 par value HSDT The Nasdaq Stock Mar
Filing Documents
- hsdt-20240627x8k.htm (8-K) — 72KB
- hsdt-20240627xex10d1.htm (EX-10.1) — 10KB
- hsdt-20240627x8k001.jpg (GRAPHIC) — 7KB
- 0001558370-24-009613.txt ( ) — 225KB
- hsdt-20240627.xsd (EX-101.SCH) — 3KB
- hsdt-20240627_lab.xml (EX-101.LAB) — 16KB
- hsdt-20240627_pre.xml (EX-101.PRE) — 10KB
- hsdt-20240627x8k_htm.xml (XML) — 5KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. At the annual meeting of stockholders of the Company held on June 27, 2024, the Company's stockholders: (i) elected six directors, each to serve for a one-year term until the 2025 annual meeting of stockholders or until his or her successor is duly elected and qualified or until his or her earlier death, resignation or removal; (ii) ratified the appointment of Baker Tilly US, LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024; (iii) approved (on an advisory basis) the compensation of the Company's named executive officers; (iv) approved the Amendment; and (v) approved authorization of one or more adjournments to the annual meeting to solicit additional proxies in the event there were insufficient votes to approve Proposal 4 described above. Proposal 1 : Election of six directors named in the accompanying proxy statement, each to serve for a one-year term until the 2025 annual meeting of stockholders or until his or her successor is duly elected and qualified or until his or her earlier death, resignation or removal. Nominee Votes For Votes Withheld Broker Non-Votes Blane Walter 766,603 150,427 499,444 Dane C. Andreeff 764,840 152,190 499,444 Edward M. Straw 755,301 161,729 499,444 Jeffrey S. Mathiesen 766,914 150,116 499,444 Paul Buckman 775,413 141,617 499,444 Sherrie Perkins 753,763 163,267 499,444 2 Proposal 2: Ratification of the appointment of Baker Tilly US, LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024: Votes For Votes Against Abstain 1,224,527 76,161 115,786 Proposal 3: Approval (on an advisory basis) of the compensation of the Company's named executive officers: Votes For Votes Against Abstain Broker Non-Votes 683,463 225,888 7,679 499,444 Proposal 4: Approval of the Amendment: Votes For Votes Against Abstain Broker
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Amendment to the Helius Medical Technologies, Inc. 2022 Equity Incentive Plan, effective as of June 27, 2024. 104 Cover Page Interactive Data File (embedded within Inline XBRL document) 3 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HELIUS MEDICAL TECHNOLOGIES, INC. Dated: June 28, 2024 By: /s/ Jeffrey S. Mathiesen Jeffrey S. Mathiesen Chief Financial Officer, Treasurer and Secretary 4